Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
168.8 USD | +0.43% |
|
+0.82% | +9.33% |
07-12 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
07-12 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.33% | 297B | |
+62.89% | 856B | |
+38.95% | 631B | |
-3.94% | 359B | |
+16.40% | 325B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.48% | 177B | |
+1.91% | 165B | |
+2.41% | 126B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-11-2017 08